Patients with ulcerative colitis who took Eli Lilly’s (NYSE:LLY) Omvoh (mirikizumab) saw significant improvements in bowel urgency frequency in a phase 3 trial.
The LUCENT-URGE study found that by week 12, patients experienced a 55% reduction in daily bowel urgency episodes compared to baseline, and severity cut by more than 50% by week 28.
Also at week 28, about one-third of patients were able to hold off going to the bathroom for at least 15 minutes after feeling urgency. At baseline, the figure was 4%.
Lilly noted that Omvoh is being evaluated in ulcerative colitis in two combination studies. One is with eltrekibart (LY3041658), a monoclonal antibody that targets neutrophil-driven inflammation. The other is with LY4268989 (MORF-057), an oral α4β7 integrin inhibitor.
